Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. [electronic resource]
Producer: 19990316Description: 747-55 p. digitalISSN:- 0732-183X
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Blood Cell Count
- Cisplatin -- administration & dosage
- Fatigue -- chemically induced
- Female
- Granulocyte Colony-Stimulating Factor -- administration & dosage
- Humans
- Infusions, Intravenous
- Middle Aged
- Nausea -- chemically induced
- Neoplasm Staging
- Neutropenia -- chemically induced
- Ovarian Neoplasms -- drug therapy
- Paclitaxel -- administration & dosage
- Thrombocytopenia -- chemically induced
- Topotecan -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.